Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 11, 2003, Pages 1462-1466

  Jakubowski, Hieronim ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

Atherosclerosis; High density lipoprotein; Homocysteine thiolactonase; Homocysteine thiolactone; Paraoxonase; Protein N homocysteinylation; S nitroso homocysteine

Indexed keywords

ALBUMIN; AMIDE; ARYLDIALKYLPHOSPHATASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; LYSINE; METHIONINE; METHIONINE TRANSFER RNA LIGASE; PEPTIDE; PROTEIN;

CHEMICAL BOND; DETOXIFICATION; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SYNTHESIS; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; PROTEIN BINDING; PROTEINS;

EID: 0344306690     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.224     Document Type: Review

References (54)

1. Mudd SH, Levy HL, Krauss JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001:2007-56.
2. Rosenblatt D, Fenton WA. Inherited disorders of folate and cobalamin transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001:3897-933.
3. Jakubowski H. Biosynthesis and reactions of homocysteine thiolactone. In: Jacobson D, Carmel R, editors. Homocysteine in health and disease. Cambridge: Cambridge University Press, UK, 2001:21-31.
4. Gow AJ, Cobb F, Stamler JS. Homocysteine, nitric oxide, and nitrosotiols. In: Jacobson D, Carmel R, editors. Homocysteine in health and disease. Cambridge: Cambridge University Press, UK, 2001:39-45.
5. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair, TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102:1227-32.
6. Seshadri S, Beiser A, Selhub J, Jaques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-83.
7. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 1999; 39: 93-109.
8. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-41.
9. Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr 2001; 131:Suppl:2983-7.
10. Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Analyt Biochem 2002; 308: 112-9.
11. Daneshvar P, Yazdanpanah M, Cuthbert C, Cole DE. Quantitative assay of plasma homocysteine thiolactone by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2003; 17:358-62.
12. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in the human. J Nutr 2000; 130 Suppl:377-81.
13. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 2002; 277:30425-8.
14. Uji Y, Motomiya Y, Hanyu N, Ukaji F, Okabe H. Protein-bound homocystamide measured in human plasma by HPLC. Clin Chem 2002; 48:941-4.
15. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275:3957-62.
16. Jakubowski H, Ambrosius W, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001; 491:35-39.
17. Jakubowski H, Fersht A. Alternative pathways of rejection of noncognate amino acids by aminoacyl-tRNA synthetases. Nucleic Acids Res 1981; 9:3105-17.
18. Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in Escherichia coli. Proc Natl Acad Sci USA 1990; 87:4504-8.
19. Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. EMBO J 1991; 10:593-8.
20. Jakubowski H, Goldman E. Editing of errors in selection of amino acids for protein synthesis. Microbiol Rev 1992; 56:412-29.
21. Jakubowski H. Proofreading in vivo: editing of homocysteine by aminoacyl-tRNA synthetases in Escherichia coli. J Biol Chem 1995; 270:17672-3.
22. Despons L, Senger B, Jakubowski H, Fasiolo F. Yeast cytoplasmic and mitochondrial methionyl-tRNA synthetases: two structural frameworks for identical functions. J Mol Biol 2001; 311:205-16.
23. Jakubowski H, Guranowski A. Metabolism of homocysteine-thiolactone in plants. J Biol Chem 2003; 278:6765-70.
24. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett 1993; 317:593-8.
25. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272:1935-42.
26. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87:45-51.
27. Jakubowski H. Synthesis of homocysteine thiolactone in normal and malignant cells. In: Graham I, Refsum H, Rosenberg IH, Ueland, PM, editors. Homocysteine metabolism: from basic science to clinical medicine. Boston, Dordrecht, London: Kluver Academic Publishers, 1997:157-65.
28. Mukai Y, Togawa T, Suzuki, Ohata K, Tanabe S. Determination of homocysteine thiolactone and homocysteine in cell cultures using high-performance liquid chromatography with fluorescence detection. J Chromatogr B 2002; 767:263-8.
29. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Eng J Med 1974; 291:537-41.
30. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced injury and atherosclerosis in baboons. Circ Res 1983; 53:731-8.
31. Mercie P, Garnier O, Lascoste L, Renard M, Closse C, Durrieu F, et al. Homocysteine thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis 2000; 5:403-11.
32. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci 2001; 68:2799-811.
33. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001; 276:35867-74.
34. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling and glutathione has a protective effect. J Mol Endocrinol 2001; 27:85-91.
35. Van Aertes LA, Klaasboer HH, Postma NS, Pertijs JC, Peereboom JH, Eskes TK, et al. Stereospecific in vitro embryo-toxicity of L-homocysteine in pre- and post-implantation rodent embryos. Toxic In Vitro 1993; 6:743-9.
36. Rosenquist TH, Finnel RH. Genes, folate and homocysteine in embryonic development. Proc Nutr See 2001; 60:53-61.
37. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13:2277-83.
38. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. J Biol Chem 1997; 272: 32370-7.
39. Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low-density lipoprotein. J Lipid Res 1998; 39:925-33.
40. Bredt DS. Nitric oxide synthases. In: Scriver, CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001: 4275-90.
41. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular dysfunction in normal human subjects. Atherosc Thromb Vasc Biol 1999; 19:2922-7.
42. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-21.
43. Borger RH, Bode-Borger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentrations of asymmetric dimethyl-arginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia and hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20:1557-64.
44. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethyl-arginine in elderly patients with stroke. Atherosclerosis 2001; 158:425-30.
45. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway; role of asymmetric dimethyl-arginine. Circulation 2001; 104:2569-75.
46. Jakubowski H. Editing of errors in amino acid selection for protein synthesis. In: Ibba M, Francklyn C, Cusack S, editors. The aminoacyl-tRNA synthetases. Georgetown, TX: Landes Bioscience, 2003. In press.
47. Jakubowski H. Translational incorporation of S-nitroso-homocysteine into protein. J Biol Chem 2000; 275:21813-6.
48. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001; 55: 443-7.
49. Peters T. All about albumin. San Diego, CA: Academic Press Inc, 1996:51-4.
50. Shih DM, Gu L, Navab M, Li WF, Hama S, Castellani LW, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-7.
51. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease that is PON1(192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-7.
52. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-7.
53. Donahue S, Sturman JA, Gaul G. Arteriosclerosis due to homocysteinemia: failure to reproduce the model in weaning rabbits. Am J Pathol 1974; 77:167-74.
54. Jakubowski H, Łaciński M, Skorupski W, Cieśliński A, Kaźmierski R, Kozubski W, et al. Homocysteine-thiolactonase activity and PON 1 genotype in coronary artery disease. J Inherit Metab Dis 2003; 26:Suppl 1:63.